Inhibiting the oncogenic mir-221 by microRNA sponge: Toward microRNA-based therapeutics for hepatocellular carcinoma

Gastroenterology and Hepatology from Bed to Bench

Volumn 7, Issue 1, 2014, Pages 43-54

  Moshiri, Farzaneh ^a,b   Callegari, Elisa ^b   D'Abundo, Lucilla ^b   Corrà, Fabio ^b   Lupini, Laura ^b   Sabbioni, Silvia ^b   Negrini, Massimo ^b  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b UNIVERSITY OF FERRARA   (Italy)

Author keywords

Adeno associated viruses; Adenoviruses; Hepatocellular carcinoma; Microrna sponge; Mir 221

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR 1B; MICRORNA 221; MICRORNA 221 SPONGE; PARVOVIRUS VECTOR; UNCLASSIFIED DRUG; VIRUS VECTOR;

ADENOVIRUS; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BINDING SITE; CELL COUNT; CELL VIABILITY; CONTROLLED STUDY; DNA MODIFICATION; GENE EXPRESSION; GENE TARGETING; GENE VECTOR; LIVER CELL CARCINOMA; LUCIFERASE ASSAY; NONHUMAN; ONCOGENE; PROTEIN EXPRESSION; VIRAL GENE DELIVERY SYSTEM;

EID: 84892450265     PISSN: 20082258     EISSN: 20084234     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. Karakatsanis A, Papaconstantinou I, Gazouli M, Lyberopoulou A, Polymeneas G, Voros D. Expression of microRNAs, miR-21, miR-31, miR-122, miR-145, miR-146a, miR-200c, miR-221, miR-222, and miR-223 in patients with hepatocellular carcinoma or intrahepatic cholangiocarcinoma and its prognostic significance. Mol Carcinog 2013;52:297-303.
2. Yoon SO, Chun SM, Han EH, Choi J, Jang SJ, Koh SA, et al. Deregulated expression of microRNA-221 with the potential for prognostic biomarkers in surgically resected hepatocellular carcinoma. Hum Pathol. 2011;42:1391-400.
3. Aravalli RN. Development of MicroRNA therapeutics for hepatocellular carcinoma. Diagnostics 2013;3:170-91.
4. Tsuchiya S, Okuno Y, Tsujimoto G. MicroRNA: biogenetic and functional mechanisms and involvements in cell differentiation and cancer. J Pharmacol Sci 2006;101:267-70.
5. Bloomston M, Frankel WL, Petrocca F, Volinia S, Alder H, Hagan JP, et al. MicroRNA expression patterns to differentiate pancreatic adenocarcinoma from normal pancreas and chronic pancreatitis. JAMA. 2007;297:1901-908.
6. Gramantieri L, Ferracin M, Fornari F, Veronese A, Sabbioni S, Liu CG, et al. Cyclin G1 is a target of miR-122a, a microRNA frequently down-regulated in human hepatocellular carcinoma. Cancer Res 2007;67:6092-99.
7. Szabo G, Bala S. MicroRNAs in liver disease. Nat Rev Gastroenterol Hepatol 2013;10:542-52.
8. Fornari F, Gramantieri L, Ferracin M, Veronese A, Sabbioni S, Calin GA, et al. MiR-221 controls CDKN1C/p57 and CDKN1B/p27 expression in human hepatocellular carcinoma. Oncogene 2008;27:5651-61.
9. Callegari E, Elamin BK, Sabbioni S, Gramantieri L, Negrini M. Role of microRNAs in hepatocellular carcinoma: a clinical perspective. Oncol Targets Ther 2013;6:1167-78.
10. Pineau P, Volinia S, McJunkin K, Marchio A, Battiston C, Terris B, et al. miR-221 overexpression contributes to liver tumorigenesis. Proc Natl Acad Sci U S A. 2010;107:264-69.
11. Liu K, Li G, Fan C, Diao Y, Wu B, Li J. Increased Expression of MicroRNA-221 in gastric cancer and its clinical significance. J Int Med Res 2012;40:467-74.
12. Quintavalle C, Garofalo M, Zanca C, Romano G, Iaboni M, del Basso De Caro M, et al. miR-221/222 overexpession in human glioblastoma increases invasiveness by targeting the protein phosphate PTPmu. Oncogene 2012;31:858-68.
13. Sharma AD, Narain N, Handel EM, Iken M, Singhal N, Cathomen T, et al. MicroRNA-221 regulates FAS-induced fulminant liver failure. Hepatology. 2011;53:1651-61
14. Yuan Q, Loya K, Rani B, Mobus S, Balakrishnan A, Lamle J, et al. MicroRNA-221 overexpression accelerates hepatocyte proliferation during liver regeneration. Hepatology 2013;57:299-310.
15. Callegari E, Elamin BK, Giannone F, Milazzo M, Altavilla G, Fornari F, et al. Liver tumorigenicity promoted by microRNA-221 in a mouse transgenic model. Hepatology 2012;56:1025-33.
16. Zhang G, Wang Q, Xu R. Therapeutics based on microRNA: a new approach for liver cancer. Curr Genomics 2010;11:311-25.
17. Reichel M, Li J, Millar AA. Silencing the silencer: strategies to inhibit microRNA activity. Biotechnol Lett 2011;33:1285-92.
18. Ebert MS, Neilson JR, Sharp PA. MicroRNA sponges: competitive inhibitors of small RNAs in mammalian cells. Nat Methods 2007;4:721-26.
19. Mukherji S, Ebert MS, Zheng GX, Tsang JS, Sharp PA, van Oudenaarden A. MicroRNAs can generate thresholds in target gene expression. Nat Genet 2011;43:854-59.
20. Ebert MS, Sharp PA. MicroRNA sponges: progress and possibilities. RNA 2010;16:2043-50.
21. Gentner B, Schira G, Giustacchini A, Amendola M, Brown BD, Ponzoni M, et al. Stable knockdown of microRNA in vivo by lentiviral vectors. Nat Methods 2009;6(1):63-6.
22. Callegari E, Elamin BK, D'Abundo L, Falzoni S, Donvito G, Moshiri F, et al. Anti-tumor activity of a miR-199-dependent oncolytic adenovirus. PLoS One 2013;8:e73964.
23. Kluiver J, Gibcus JH, Hettinga C, Adema A, Richter MK, Halsema N, et al. Rapid generation of microRNA sponges for microRNA inhibition. PLoS One 2012;7:e29275.
24. McCarty DM. Self-complementary AAV vectors; advances and applications. Mol Ther 2008;16:1648-56.
25. Grimm D, Lee JS, Wang L, Desai T, Akache B, Storm TA, et al. In vitro and in vivo gene therapy vector evolution via multispecies interbreeding and retargeting of adeno-associated viruses. J Virol 2008;82:5887-911.
26. Stenvang J, Petri A, Lindow M, Obad S, Kauppinen S. Inhibition of microRNA function by antimiR oligonucleotides. Silence 2012;3:1.
27. Grimm D. Small silencing RNAs: state-of-the-art. Adv Drug Deliv Rev 2009;61:672-703.
28. Kota J, Chivukula RR, O'Donnell KA, Wentzel EA, Montgomery CL, Hwang HW, et al. Therapeutic microRNA delivery suppresses tumorigenesis in a murine liver cancer model. Cell 2009;137:1005-17.
29. Schnepp BC, Clark KR, Klemanski DL, Pacak CA, Johnson PR. Genetic fate of recombinant adenoassociated virus vector genomes in muscle. J Virol 2003;77:3495-504.
30. Gao GP, Lu F, Sanmiguel JC, Tran PT, Abbas Z, Lynd KS, et al. Rep/Cap gene amplification and highyield production of AAV in an A549 cell line expressing Rep/Cap. Mol Ther 2002;5:644-49.
31. Park K, Kim WJ, Cho YH, Lee YI, Lee H, Jeong S, et al. Cancer gene therapy using adeno-associated virus vectors. Front Biosci 2008;13:2653-59.
32. Carter BJ. Adeno-associated virus vectors in clinical trials. Hum Gene Ther 2005;16:541-50.
33. Garofalo M, Di Leva G, Romano G, Nuovo G, Suh SS, Ngankeu A, et al. miR-221&222 regulate TRAIL resistance and enhance tumorigenicity through PTEN and TIMP3 downregulation. Cancer Cell 2009;16:498-509.
34. Pallante P, Visone R, Ferracin M, Ferraro A, Berlingieri MT, Troncone G, et al. MicroRNA deregulation in human thyroid papillary carcinomas. Endocr Relat Cancer 2006;13:497-508.